<DOC>
	<DOC>NCT02137083</DOC>
	<brief_summary>Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast Cancer</brief_summary>
	<brief_title>A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer</brief_title>
	<detailed_description>Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal female between 18 and 70 years old ECOG performance status of ≤ 1 Life expectancy more than 3 months Histologically confirmed metastatic breast cancer ER and&amp;or PR pqositive, HER2negative Disease progression during adjuvant or firstline endocrine therapy, or endocrine naive but unsuitable for endocrine therapy alone No pretreated chemotherapy for metastatic disease Have at least one target lesion according to RECIST 1.1 No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4 weeks before enrollment Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10^9/L, Platelet Count ≥ 75×10^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance＞50ml/min Pregnant or lactating women Evidence of CNS metastasis Seriously uncontrolled infection History of another malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix Pretreated with Fulvestrant Pretreated with two or more lines of endocrine therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Endocrine therapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Fulvestrant</keyword>
</DOC>